Shots:
- The company initiates P-III OASIS program to evaluate the efficacy and safety of elinzanetant (120mg, qd) in 1300 patients with vasomotor symptoms during menopause at 200+ centers across 20+ countries
- The design and dosing of the P-III clinical development program is based on the results from two P-II studies i.e., P-Ib/IIa RELENT-1 & P-IIb SWITCH-1 study for elinzanetant
- The therapy is currently under development as a non-hormonal, dual neurokinin-1,3 receptor antagonist. In Sept’20, Bayer has completed the acquisition of KaNDy to expand its drug development pipeline in women’s healthcare
Click here to read full press release/ article | Ref: Businesswire | Image: Shanghai Daily
The post Bayer Initiates P-III OASIS Program of Elinzanetant for the Treatment of Vasomotor Symptoms During Menopause first appeared on PharmaShots.
